

Figure S1. Effects of doxorubicin on modulation of TRAIL receptor, FasR, MIC-A/B, HLA class I and PD-L1 expression in MDA-MB-231 cells. The MDA-MB-231 cells were treated with a sublethal dose of doxorubicin (160 nM). The histogram represents the percentage of positive cells expressing TRAIL receptors, FasR, MIC-A/B, HLA class I and PD-L1 protein after a 24-h treatment with doxorubicin. TRAIL, TNF-related apoptosis-inducing ligand; FasR, Fas receptor; HLA, human leukocyte antigen; PD-L1, programmed death-ligand 1.




Figure S2. Effects of doxorubicin on modulation of TRAIL receptor, FasR, MIC-A/B, HLA class I and PD-L1 expression in MCF7 cells. The MCF7 cells were treated with a sublethal dose of doxorubicin (160 nM). The histograms represent the percentage of positive cells expressing TRAIL receptors, FasR, MIC-A/B, HLA class I and PD-L1 protein after a 24-h treatment with doxorubicin. TRAIL, TNF-related apoptosis-inducing ligand; FasR, Fas receptor; HLA, human leukocyte antigen; PD-L1, programmed death-ligand 1.




Figure S3. Dose-dependent effects of doxorubicin on modulation of FasR in MCF7 cells. The MCF7 cells were treated with various doses of doxorubicin (40, 80 and 160 nM). The histograms represent the percentage of positive cells expressing FasR after a 24-h treatment with doxorubicin. FasR, Fas receptor.

